Learn more about NGS to test for oncogenic alterations in mNSCLC  
 
     
 
 
  YOUR NOVARTIS ONCOLOGY SALES SPECIALIST  
 
{{userPhoto}}
 
{{userName}}
{{user.Phone}}
 
     
 
  Dear {{customText[Dr|Mr|Mrs|Ms]}} {{accLname}}:  
 
  {{customText[Thank you for taking the time to meet with me. You requested more information, and I am following up with relevant material.|I'm sorry we missed each other when I stopped by your office. However, below is information for your review.|It's been a while since our last meeting, so I am sharing some information that may interest you.|Per our recent conversation, I would like to share information that may be useful to you, your staff, and your patients with non-small cell lung cancer.|Below is additional information regarding our recent discussion.|I am following up with you regarding some relevant information I left with you.|It was good speaking with you recently. I am providing you with additional information, as discussed.|It was a pleasure speaking with you. As requested, I’m following up with further information.]}}  
 
     
 
  START WITH NGS, BECAUSE KNOWING THE GENOMIC MUTATION STATUS OF YOUR PATIENTS WITH METASTATIC NSCLC CAN INFORM CLINICAL DECISIONS  
 
  NGS offers1  
 
  • A thorough genomic profile with one test, using a single tissue sample  
 
  • Comprehensive identification of oncogenic alterations, such as ALK, BRAF, EGFR, and ROS-1  
 
 
 
  NGS is reimbursed by Medicare as of March 2018, with no 14-day waiting period2,3  
 
 
 
 
     
 
{{insertEmailFragments[2,2]}}
  ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; mNSCLC, metastatic non-small cell lung cancer; NGS, next-generation sequencing.  
 
     
 
  {{customText[Should you like to follow up, I would be happy to share more information with you. Please call me at the number below.|Because we haven't met recently, I invite you to call me to arrange a time when we can discuss additional information.|Thank you for reviewing this information. I hope you found it useful. Please do not hesitate to call me if you have any questions about the information provided or would like additional materials.|Because you requested this information, I wanted to answer any questions you may have. Please don't hesitate to call me if there is anything else you need.|If you have any questions, please call me for additional information.|Should you require more information, it would be my pleasure to speak to you. Please let me know when it would be a good time to talk.]}}  
 
  {{customText[Sincerely,|Best regards,|Thank you,|Respectfully yours,|Yours truly,]}}
{{userName}}
{{user.Phone}}		  
 
     
 
  References: 1. Drilon A, Wang L, Arcila M, et al. Broad, hybrid capture–based next- generation sequencing identifies actionable genomic alterations in lung adenocarcinomas otherwise negative for such alterations by other genomic testing approaches. Clin Cancer Res. 2015;21(16):3631-3639. 2. Centers for Medicare and Medicaid Services: CMS finalizes coverage of Next Generation Sequencing tests, ensuring enhanced access for cancer patients. h‍ttps://w‍ww.cms.gov/Newsroom/MediaReleaseDatabase/Press-releases/2018-Press-releases-items/2018-03-1‍6.htm‍l. Accessed April 23, 2019. 3. Data on file. Novartis Pharma AG.  
 
     
 
  If you have any questions concerning e-mail or marketing communications from Novartis Pharmaceuticals Corporation, please call 1-888-NOW-NOVA (1-888-669-6682), Monday to Friday, 8:30 AM to 5:00 PM ET.  
 
  If you prefer not to receive e-mail communications about Lung Oncology in this channel, please click here.  
 
  For more information, please visit the Novartis Privacy Policy.